Advertisement

Cancer Causes & Control

, Volume 30, Issue 1, pp 103–112 | Cite as

CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy

  • Sophie E. MayerEmail author
  • Noel S. Weiss
  • Jessica Chubak
  • David R. Doody
  • Christopher S. Carlson
  • Karen W. Makar
  • Michelle A. Wurscher
  • Kathleen E. Malone
Original paper
First Online:
  • 87 Downloads

Abstract

Purpose

Tamoxifen is widely used to reduce the risk of breast cancer (BC) recurrence and extend disease-free survival among women with estrogen-sensitive breast cancers. Tamoxifen efficacy is thought to be attributable to its active metabolite, which is formed through a reaction catalyzed by the P450 enzyme, CYP2D6. Inhibition of tamoxifen metabolism as a result of germline genetic variation and/or use of CYP2D6-inhibiting medications (“inhibitors”) is hypothesized to increase the risk of adverse BC outcomes among women taking tamoxifen.

Methods

The present cohort study of 960 women diagnosed with early-stage BC between 1993 and 1999 examined the association between concomitant use of CYP2D6 inhibitors and adjuvant tamoxifen and the risk of adverse BC outcomes (recurrence, second primary BC, BC mortality), both overall and according to CYP2D6 metabolic phenotype.

Results

Six or more months of CYP2D6 inhibitor use concomitant with tamoxifen was not associated with any appreciable increase in risk of recurrence or second primary BC or BC mortality, and there was no clear evidence of variation by CYP2D6 metabolic phenotype.

Conclusions

These results are consistent with the relatively few other large, population-based studies conducted to date that have not observed an increased risk of adverse BC outcomes associated with CYP2D6 inhibition.

Keywords

CYP2D6 Tamoxifen Breast cancer Survival Pharmacogenetics 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This research was supported by the following National Cancer Institute grants issued to the Fred Hutch/University of Washington: CA173795, CA098858, CA015704, and CA009168. We are very grateful for the generous contributions of our study participants and research team.

Funding

This research was supported by NIH Grants R01 CA098858, R03 CA173795, and T32 CA009168. This research was also supported in part through the NIH/NCI Cancer Center Support Grant P30 CA015704.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

References

  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717CrossRefGoogle Scholar
  2. 2.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784CrossRefGoogle Scholar
  3. 3.
    Davies C, Pan H, Godwin J, Gray R, Arriagada R et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE et al (2014) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology Clinical Practice guideline focused update. J Clin Oncol 32(21):2255–2269PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Jin Y, Desta Z, Stearns V, Ward B, Ho H et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39PubMedCrossRefGoogle Scholar
  6. 6.
    Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM et al (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151–159PubMedCrossRefGoogle Scholar
  7. 7.
    Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471–478PubMedCrossRefGoogle Scholar
  8. 8.
    Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764PubMedCrossRefGoogle Scholar
  9. 9.
    Stearns V, Rae JM (2008) Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med 10:e34PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T et al (2008) Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112(1):123–132PubMedCrossRefGoogle Scholar
  12. 12.
    Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE et al (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19(1):56–61PubMedCrossRefGoogle Scholar
  13. 13.
    Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G et al (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89(5):708–717PubMedCrossRefGoogle Scholar
  14. 14.
    Hennig EE, Piatowska M, Karczmarski J, Goryca K, Brewczynska E et al (2015) Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer. BMC Cancer 15:570PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Schroth W, Winter S, Mürdter T et al (2017) Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen. Front Pharmacol 8:582PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A et al (2004) Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10(7):2336–2343PubMedCrossRefGoogle Scholar
  17. 17.
    Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE et al (2014) Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 95(4):376–382PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Binkhorst L, Mathijssen RH, Jager A, van Gelder T (2015) Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev 41(3):289–299PubMedCrossRefGoogle Scholar
  19. 19.
    Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype and breast cancer outcomes. Clin Pharmacol Ther 89(5):718–725PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Borges S, Desta Z, Li L, Skaar TC, Ward BA et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80(1):61–74PubMedCrossRefGoogle Scholar
  21. 21.
    Saladores P, Mürdter T, Eccles D, Chowbay B, Zgheib NK et al (2015) Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 15(1):84–94PubMedCrossRefGoogle Scholar
  22. 22.
    Helland T, Henne N, Bifulco E, Naume B, Borgen E et al (2017) Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res 19:125PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Johansson H, Gandini S, Serrano D, Gjerde J, Lattanzi M et al (2016) A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. Breast Cancer Res Treat 159(1):97–108PubMedCrossRefGoogle Scholar
  24. 24.
    Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C et al (2018) Tamoxifen metabolism and efficacy in breast cancer: a prospective multicenter trial. Clin Cancer Res 24(10):2312–2318PubMedCrossRefGoogle Scholar
  25. 25.
    Schroth W, Antoniadou L, Fritz P, Schwab M, Mürdter T et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25(33):5187–5193PubMedCrossRefGoogle Scholar
  26. 26.
    Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13):1429–1436PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M et al (2013) CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 19(2):500–507PubMedCrossRefGoogle Scholar
  28. 28.
    Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M et al (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125(1):279–287PubMedCrossRefGoogle Scholar
  29. 29.
    Chubak J, Bowles EJA, Yu O, Buist DSM, Fujii M et al. Boudreau DM. (2016). Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control. 27(1):125–136Google Scholar
  30. 30.
    Dezentjé VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP et al (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28(14):2423–2429PubMedCrossRefGoogle Scholar
  31. 31.
    Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL et al (2010) Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 49(3):305–312PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL et al (2011) CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 103(6):489–500PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Azoulay L, Dell’Aniello S, Huiart L, du Fort GG, Suissa S (2011) Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 126(3):695–703PubMedCrossRefGoogle Scholar
  34. 34.
    Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W et al Breast International Group (BIG) 1–98 Collaborative Group. (2012). CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J Natl Cancer Inst. 104(6):441–451PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104(6):452–460PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Markkula A, Hjertberg M, Rose C, Ingvar C, Jernström H (2014) No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients. Acta Oncol 53(2):195–200PubMedCrossRefGoogle Scholar
  37. 37.
    Haque R, Shi J, Schottinger JE, Ahmed SA, Cheetham TC et al (2016) Tamoxifen and antidepressant drug interaction among a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst 108(3):djv337CrossRefGoogle Scholar
  38. 38.
    Hertz DL, Kidwell KM, Hilsenbeck SG et al (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166(1):277–287PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Donneyong MM, Bykov K, Bosco-Levy P, Dong YH, Levin R, Gagne JJ (2016) Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ 354:i5014PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Reding KW, Doody DR, McTiernan A, Hsu L, Davis S et al (2011) Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat 126(3):749–761PubMedCrossRefGoogle Scholar
  41. 41.
    Marchbanks PA, McDonald JA, Wilson HG, Burnett NM, Daling JR et al (2002) The NICHD Women’s Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol 12(4):213–221PubMedCrossRefGoogle Scholar
  42. 42.
    Li CI, Malone KE, Porter PL, Weiss NS, Tang MT et al (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289(24):3254–3263PubMedCrossRefGoogle Scholar
  43. 43.
    Davis S, Mirick DK, Stevens RG (2002) Residential magnetic fields and the risk of breast cancer. Am J Epidemiol 155(5):446–454PubMedCrossRefGoogle Scholar
  44. 44.
    Food US, Administration D (2016) Table 3–2: Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical DDI studies and/or drug labeling). https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2. Accessed 8 Jan 2018
  45. 45.
    Indiana University Clinical Pharmacology Research Institute (2016) Flockhart™ P450 Drug interaction table–inhibitors. http://medicine.iupui.edu/clinpharm/ddis/main-table. Accessed 8 Jan 2018
  46. 46.
    Lyon E, Gastier Foster JM, Palomaki GE, Pratt VM, Reynolds K et al, working group of the Molecular Genetics Subcommittee on behalf of the American College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance Committee (2012) Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genet Med 14(12):990–1000PubMedCrossRefGoogle Scholar
  47. 47.
    Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG et al (2015) In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. Br J Clin Pharmacol 80(5):1122–1130PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Cronin-Fenton DP, Lash TL (2011) Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol 4(3):363–377PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10(8):825–833PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Malone KE, Daling JR, Doody DR, O’Brien C, Resler A et al (2011) Family history of breast cancer in relation to tumor characteristics and mortality in a population–based study of young women with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 20(12):2560–2571PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM et al (2014) Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst 107(2):dju401PubMedPubMedCentralGoogle Scholar
  52. 52.
    Ahern TP, Hertz DL, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ et al (2017) Cytochrome P-450 2D6 (CYP2D6) genotype and breast cancer recurrence in tamoxifen-treated patients: evaluating the importance of loss of heterozygosity. Am J Epidemiol 185(2):75–85PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Ekholm M, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Rydén L (2016) Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: long-term follow-up (> 25 years) of the phase III SBII:2pre trial. J Clin Oncol 34(19):2232–2238PubMedCrossRefGoogle Scholar
  54. 54.
    Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115(22):5349–5361PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Sophie E. Mayer
    • 1
    • 2
    Email author
  • Noel S. Weiss
    • 2
    • 3
  • Jessica Chubak
    • 2
    • 4
  • David R. Doody
    • 3
  • Christopher S. Carlson
    • 3
  • Karen W. Makar
    • 5
  • Michelle A. Wurscher
    • 3
  • Kathleen E. Malone
    • 2
    • 3
  1. 1.University of North Carolina at Chapel HillChapel HillUSA
  2. 2.University of WashingtonSeattleUSA
  3. 3.Fred Hutchinson Cancer Research CenterSeattleUSA
  4. 4.Kaiser Permanente Washington Health Research InstituteSeattleUSA
  5. 5.Bill & Melinda Gates FoundationSeattleUSA

Personalised recommendations

Cite article

Buy options